BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.19836
Abstract: Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval… read more here.
Keywords: inhibitors resistance; combination; resistance promise; combination treatments ... See more keywords